Alessandra Pulvirenti1, Deepthi Rao2, Caitlin A Mcintyre1, Mithat Gonen3, Laura H Tang2, David S Klimstra2, Martin Fleisher4, Lakshmi V Ramanathan4, Diane Reidy-Lagunes5, Peter J Allen6. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: allenp@mskcc.org.
Abstract
BACKGROUND: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs. METHODS: Patients with well-differentiated PanNET and a baseline CgA measurement, between 2011 and 2016 were reviewed. The diagnostic value was determined by comparing CgA values from patients with PanNETs to those with other pancreatic neoplasms and healthy controls. The Kaplan-Meier method was used to investigate the CgA prognostic significance. RESULTS: Ninety-nine patients met inclusion criteria. As a diagnostic marker, CgA had a sensitivity of 66%, specificity of 95%, and overall accuracy of 71%. The use of PPIs was associated with a higher CgA level (p = 0.015). When excluding patients on PPIs, CgA accuracy in distinguishing PanNETs from other pancreatic neoplasms was 66%, the sensitivity and specificity were 60% and 75% respectively. Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival. CONCLUSION: CgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors.
BACKGROUND: Serum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs. METHODS: Patients with well-differentiated PanNET and a baseline CgA measurement, between 2011 and 2016 were reviewed. The diagnostic value was determined by comparing CgA values from patients with PanNETs to those with other pancreatic neoplasms and healthy controls. The Kaplan-Meier method was used to investigate the CgA prognostic significance. RESULTS: Ninety-nine patients met inclusion criteria. As a diagnostic marker, CgA had a sensitivity of 66%, specificity of 95%, and overall accuracy of 71%. The use of PPIs was associated with a higher CgA level (p = 0.015). When excluding patients on PPIs, CgA accuracy in distinguishing PanNETs from other pancreatic neoplasms was 66%, the sensitivity and specificity were 60% and 75% respectively. Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival. CONCLUSION: CgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors.
Authors: S Sanduleanu; M Stridsberg; D Jonkers; W Hameeteman; I Biemond; G Lundqvist; C Lamers; R W Stockbrügger Journal: Aliment Pharmacol Ther Date: 1999-02 Impact factor: 8.171
Authors: Wei Qiu; Ioannis Christakis; Angelica Silva; Roland L Bassett; Liyun Cao; Qing H Meng; Elizabeth Gardner Grubbs; Hua Zhao; James C Yao; Jeffrey E Lee; Nancy D Perrier Journal: Clin Endocrinol (Oxf) Date: 2016-06-30 Impact factor: 3.478
Authors: Irvin M Modlin; Mark Kidd; Kjell Oberg; Massimo Falconi; Pier Luigi Filosso; Andrea Frilling; Anna Malczewska; Ronald Salem; Christos Toumpanakis; Faidon-Marios Laskaratos; Stefano Partelli; Matteo Roffinella; Claudia von Arx; Beata Kos Kudla; Lisa Bodei; Ignat A Drozdov; Alexandra Kitz Journal: Ann Surg Oncol Date: 2021-05-18 Impact factor: 5.344
Authors: Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi Journal: Front Mol Biosci Date: 2019-10-18
Authors: Martina Hinterleitner; Bence Sipos; Verena Wagner; Julia M Grottenthaler; Ulrich M Lauer; Lars Zender; Clemens Hinterleitner Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639
Authors: Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes Journal: Pancreas Date: 2021-02-01 Impact factor: 3.243